Treatment
Ipilimumab clinical trials
We’re tracking 120 recruiting studies that include Ipilimumab, each written for real people, not researchers, below.
Recruiting studies
- NCT07147101Recruiting
Immunotherapy for advanced liver cancer: a study on effectiveness and immune response
This study looks at different first-line immunotherapy treatments for people with advanced liver cancer that cannot be treated with surgery or local therapies. It aims to understand how well these treatments work and how they affect the body's immune system.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05384496RecruitingPhase 2
Axitinib and nivolumab for advanced mucosal melanoma
This trial studies how well two medicines—axitinib and nivolumab—work for people with advanced melanoma that starts in moist “mucosal” areas (like the mouth, nose, throat, or bowel). It may help shrink tumors and control the disease by boosting the immune system and targeting tumor growth.
Harrison, New YorkAges 18 years+ - NCT06163820RecruitingPhase 1/Phase 2
Bevacizumab and immunotherapy with radiation for melanoma brain metastases
This trial tests a combination of a drug that stops blood vessel growth (bevacizumab), immunotherapy, and focused radiation to treat melanoma that has spread to the brain and is causing symptoms. The goal is to see if this approach shrinks tumors and improves outcomes.
Melbourne, VictoriaAges 18 years+ - NCT07190677Recruiting
Nivolumab plus ipilimumab with chemo for advanced lung cancer
This trial tests combining two immunotherapy drugs (nivolumab and ipilimumab) with chemotherapy as a first treatment for advanced lung cancer that has spread or come back. It may help if your cancer hasn't been treated before and doesn't have certain genetic changes.
Pavia, LombardyAges Any age - NCT05584670RecruitingPhase 1/Phase 2
Testing a new cancer drug for advanced solid tumors
This is an early (Phase 1/2) study of SAR445877, a new drug, in adults with advanced or metastatic solid cancers. It aims to find the safest dose and learn whether it can shrink tumors or help control disease when standard treatments aren’t available or no longer work.
Newark, DelawareAges 18 years+ - NCT07611825RecruitingPhase 2
Gut Bacteria Treatment for Advanced Kidney Cancer Resistant to Immunotherapy
This study tests whether modifying your gut bacteria can help immunotherapy work again in advanced kidney cancer that has stopped responding to initial immune-checkpoint inhibitor treatment. Researchers will give you a special bacterial preparation along with a new immunotherapy drug to see if this combination can slow or shrink your cancer.
Nanjing, JiangsuAges 18–90 - NCT05647265RecruitingPhase 2
Immunotherapy before surgery for sarcomatoid pleural mesothelioma
This trial tests adding immunotherapy before surgery to help patients with sarcomatoid pleural mesothelioma. The goal is to shrink or control the cancer and make surgery possible, while checking safety.
Anchorage, AlaskaAges 18 years+ - NCT06514651RecruitingPhase 1
MAQ-001 for advanced solid tumors after PD-1/PD-L1 therapy
This study tests a new experimental drug called MAQ-001 in people with advanced solid tumors or lymphomas that have already been treated with a PD-1/PD-L1 checkpoint inhibitor. The goal is to see if MAQ-001 can shrink or control the cancer when other treatments are no longer working.
LyonAges 18 years+ - NCT05876715RecruitingPhase 1/Phase 2
Testing 3 immunotherapy drugs for hard-to-remove soft tissue cancer
This Phase 1/2 study tests lurbinectedin plus two immune checkpoint medicines (ipilimumab and nivolumab) for soft tissue sarcoma that is hard to remove or has spread. It aims to see how well the combination works and how safe it is, especially for people with limited treatment options.
Santa Monica, CaliforniaAges 18–90 - NCT07482059RecruitingPhase 1/Phase 2
Combination therapy for advanced liver cancer
This trial tests a combination of treatments for liver cancer that cannot be removed by surgery. It uses a special radiation therapy called Y90 along with other drugs to see if they work better together.
Chengdu, SichuanAges 18–80 - NCT05176483RecruitingPhase 1
New drug combinations for advanced solid tumors
This trial tests a new drug called zanzalintinib, which may slow or shrink various types of advanced cancer. It is given together with other cancer treatments, and the study is looking at many different cancers including kidney, prostate, bladder, lung, liver, and more.
Phoenix, ArizonaAges 18 years+ - NCT07227012RecruitingPhase 1/Phase 2
Study of a new drug for advanced liver cancer
This trial tests a new medicine, PF-08634404, alone or with other treatments for adults with advanced liver cancer that cannot be removed by surgery or has spread. It is for people who have not had prior systemic therapy and have good liver function.
Los Angeles, CaliforniaAges 18 years+ - NCT07230613RecruitingPhase 2
Immunotherapy before surgery for localized melanoma
This trial tests if giving two immunotherapy drugs (nivolumab and ipilimumab) before surgery can improve outcomes for patients with stage III melanoma that can be removed. It is for people who have not had certain treatments recently or whose melanoma is not in the eye.
BordeauxAges 18 years+ - NCT06047379RecruitingPhase 1/Phase 2
Testing NEO212 for brain tumors and metastases
This trial tests a new drug called NEO212 for people with certain brain tumors (like astrocytoma or glioblastoma) or cancer that has spread to the brain from other parts of the body. The goal is to see if it is safe and if it can help shrink or control the tumors.
Beverly Hills, CaliforniaAges 18 years+ - NCT03017820RecruitingPhase 1
Vaccine plus immune drugs for relapsed blood cancers
This early-phase trial tests a personalized-style vaccine (called VSV-hIFNβ-NIS) given alone or with other cancer-fighting medicines, including drugs that help the immune system attack. It is designed for people with certain relapsed or hard-to-treat multiple myeloma, acute myeloid leukemia, or lymphomas, to see if the treatment can shrink tumors and improve outcomes.
Scottsdale, ArizonaAges 18 years+ - NCT03026140RecruitingPhase 2
Tested immune therapy before surgery for early colon cancer
This Phase 2 trial tests immune “checkpoint” medicines (and combinations) given before colon surgery to see if they can better control early colon cancer. It is aimed at people with non-metastatic colon cancer and certain tumor markers.
AmsterdamAges 18 years+ - NCT03297606RecruitingPhase 2
Match your tumor test to a targeted cancer drug
This trial studies whether giving a targeted cancer medicine based on tumor genetic/protein test results can help people with advanced, incurable cancers live longer. You may be eligible if your cancer has a “potentially actionable” change on testing and you meet health and follow-up requirements.
Edmonton, AlbertaAges 18 years+ - NCT03340129RecruitingPhase 2
Nivolumab plus focused brain radiation for melanoma spread
This trial studies whether giving the immunotherapy drug nivolumab together with targeted brain radiation (not whole-brain radiation) helps people with melanoma that has spread to the brain. It aims to improve brain control while keeping side effects manageable.
Sydney, New South WalesAges 18–120 - NCT03406247RecruitingPhase 2
Immunotherapy after salvage surgery for head and neck cancer
This Phase 2 trial tests an immunotherapy given after salvage surgery for certain head and neck squamous cell cancers that came back (or a new second cancer) in an area that was already treated with radiation. It aims to lower the chance the cancer returns after surgery, especially in higher-risk situations.
Villejuif, Val De MarneAges 18 years+ - NCT03563729RecruitingPhase 2
Melanoma in the brain: steroids plus targeted therapy
This Phase 2 trial studies how giving steroid medicine for brain swelling may help people with melanoma that has spread to the brain, and whether adding a targeted approach works for a specific genetic tumor type. It may help shrink brain tumors and improve symptoms, while comparing how patients respond.
Herlev, Capital RegionAges 18 years+ - NCT03646617RecruitingPhase 2
Testing immunotherapy with or without targeted radiation for melanoma
This trial studies whether combining two immunotherapy medicines (ipilimumab and nivolumab) works better with targeted radiation for metastatic melanoma that has specific treatable spots. It may help shrink tumors and improve control of the disease, depending on your individual situation.
Lancaster, PennsylvaniaAges 18 years+ - NCT03815890RecruitingPhase 2
Pre-surgery nivolumab for certain types of breast cancer
This trial tests whether giving nivolumab before surgery (neoadjuvant treatment) can improve outcomes for people with certain resectable breast cancers. It focuses on tumor types linked to immune activity (like triple-negative and specific lab markers).
AmsterdamAges 18 years+ - NCT03816345RecruitingPhase 1
Nivolumab for advanced cancer with autoimmune conditions
This Phase 1 study tests nivolumab, an immunotherapy “anti-cancer accelerator,” in people with advanced cancer who also have an autoimmune disorder. It aims to see if nivolumab can be given safely and whether it may help shrink or control cancer.
Birmingham, AlabamaAges 18 years+ - NCT03899155RecruitingPhase 2
Study for continuing or restarting cancer treatment that worked before
This trial lets people who were already in a related “parent” study either keep taking treatment or restart it after it had stopped working for a while. It’s meant for people who previously had a meaningful response and may still benefit from continued treatment.
Huntsville, AlabamaAges 18 years+
Common questions
- Are there clinical trials studying Ipilimumab?
- Yes. Clin2 currently lists 120 recruiting studies that include Ipilimumab, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Ipilimumab trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Ipilimumab an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Ipilimumab or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.